PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 µM, JNK2 at 0.831 µM, and JNK3 at 0.285 µM. It also inhibits SGK isoforms (SGK1: IC50=1.34 µM, SGK2: IC50=5.6 µM, SGK3: IC50=26.4 µM) and ROCK2 (IC50=34 µM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.
Molecular Weight:
429.64
CAS Number:
[2059104-90-2]
Formula:
C23H31N3OS2
Target:
SGK|||ROCK|||JNK
T201273
* VAT and and shipping costs not included. Errors and price changes excepted
